MedTrace Logo

Clinical Pharmacogenomics of Antidepressant Response

NCT00384020 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 402

Last updated 2010-02-01

No results posted yet for this study

Summary

The purpose of this study is to understand how genetic polymorphisms influence the efficacy and side effect profiles of Paroxetine and Escitalopram for major depression treatment.

Conditions

Interventions

DRUG

Paroxetine (Seroxat)

DRUG

Escitalopram (Lexapro)

Sponsors & Collaborators

  • National Science and Technology Council, Taiwan

    collaborator OTHER_GOV

  • Chang Gung Memorial Hospital

    collaborator OTHER

  • Taipei Medical University WanFang Hospital

    collaborator OTHER

  • Taipei City Hospital

    collaborator OTHER_GOV

  • Mackay Memorial Hospital

    collaborator OTHER

  • National Health Research Institutes, Taiwan

    lead OTHER

Principal Investigators

  • Keh-Ming Lin, MD, MPH · National Health Research Institutes, Taiwan

  • Chia-Hui Chen, MD · National Health Research Institutes, Taiwan

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2010-01-31
Completion
2010-01-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00384020 on ClinicalTrials.gov